Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) price on Wednesday, December 04, fall -3.89% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.69.
A look at the stock’s price movement, the close in the last trading session was $0.71, moving within a range at $0.676 and $0.7201. The beta value (5-Year monthly) was 1.244. Turning to its 52-week performance, $3.73 and $0.70 were the 52-week high and 52-week low respectively. Overall, LXRX moved -43.14% over the past month.
Lexicon Pharmaceuticals Inc’s market cap currently stands at around $247.70 million, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 6.48M for the company’s revenue for the quarter, with a low and high estimate of 2M and 26.7M respectively. The average forecast suggests up to a 822.99% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 11.13M, representing a 824.52% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that LXRX is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend LXRX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
LXRX’s current price about -28.00% and -51.17% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 23.39, while 7-day volatility ratio is 7.74% and 10.23% in the 30-day chart. Further, Lexicon Pharmaceuticals Inc (LXRX) has a beta value of 1.06, and an average true range (ATR) of 0.10. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is -769.57% off current price level while to achieve the yearly target high, price needs to move -769.57%. Nonetheless, investors will most likely welcome a -769.57% jump to $6 which is the analysts’ median price.
If we refocus on Lexicon Pharmaceuticals Inc (NASDAQ:LXRX), historical trading data shows that trading volumes averaged 3.74 over the past 10 days and 3.28 million over the past 3 months. The company’s latest data on shares outstanding shows there are 361.49 million shares.
The 53.35% of Lexicon Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 29.64% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 31.38 million on 2024-11-15, giving us a short ratio of 7.49. The data shows that as of 2024-11-15 short interest in Lexicon Pharmaceuticals Inc (LXRX) stood at 1925.0 of shares outstanding, with shares short rising to 27.65 million registered in 2024-10-15. Current price change has pushed the stock -55.22% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the LXRX stock continues to rise going into the next quarter.
